> 首页 > 产品 > 一抗 > 精选抗体 > Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab)

Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab)

Recombinant Antibody

Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab) is 100%, determined by SEC-HPLC.
Immobilized human CD27 FC at 2 ug/mL can bind Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab), EC50=0.01912 ug/mL.
Human CD27 HEK293 cells were stained with Anti-TNFRSF7 / CD27 Reference Antibody (varlilumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.095 ug/mL.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P26842
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	29137 Da

Additional Information
Target/Specificity	TNFRSF7 / CD27
Endotoxin	< 0.001EU/ µg,determined by LAL method.
Conjugation	Unconjugated
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.

Protein Information
Name	CD27 (HGNC:11922)
Function	Costimulatory immune-checkpoint receptor expressed at the surface of T-cells, NK-cells and B-cells which binds to and is activated by its ligand CD70/CD27L expressed by B-cells (PubMed:28011863). The CD70-CD27 signaling pathway mediates antigen- specific T-cell activation and expansion which in turn provides immune surveillance of B-cells (PubMed:28011863). Mechanistically, CD70 ligation activates the TRAF2-PTPN6 axis that subsequently inhibits LCK phosphorylation to promote phenotypic and transcriptional adaptations of T-cell memory (PubMed:38354704). In addition, activation by CD70 on early progenitor cells provides a negative feedback signal to leukocyte differentiation during immune activation and thus modulates hematopoiesis (By similarity). Negatively regulates the function of Th2 lymphocytes in the adipose tissue (By similarity).
Cellular Location	Cell membrane; Single-pass type I membrane protein
Tissue Location	Found in most T-lymphocytes.